Explanipedia

The prognostic impact of chromosome 7 with both arms loss [der(7)del(7p)del(7q)] in myelodysplastic syndrome/neoplasm Open

Ji Zhou, Linlin Liu, Chenghua Cui, Chengwen Li, Yujiao Jia , et al. · 2025

Der(7) defines a distinct high-risk subgroup with a unique molecular profile and poor prognosis comparable to -7.

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms Open

Junying Wu, Jinqin Liu, Jia Chen, Lin Yang, Fuhui Li , et al. · 2025

Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes Open

Zhiwei Bao, Bing Li, Tiejun Qin, Zefeng Xu, Shiqiang Qu , et al. · 2025

Comprehensive genomic characterization of programmed cell death-related genes to predict drug resistance and prognosis for patients with multiple myeloma Open

Yan Li, Fuxu Wang, Hongbo Zhao, Zhenwei Jia, Xiaoyan Liu , et al. · 2025

A 12-gene Risk score model developed with PCD-related genes can accurately predict the survival for MM patients. Our study provided potential targets and strategies for individualized treatment of MM.

Targeting CD38 effectively prevents myelofibrosis in myeloproliferative neoplasms Open

Yiru Yan, Jinqin Liu, Sophia Zhao, Fuhui Li, Lin Yang , et al. · 2025

Proinflammatory signaling is a hallmark of myeloproliferative neoplasms (MPNs). Several studies have shown that monocytes are a major source of proinflammatory cytokines and monocyte-derived fibrocytes play a pivotal role in the pathogenes…

Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion Open

Yanan Chang, Linlin Liu, Chenghua Cui, Jiange He, Chengwen Li , et al. · 2025

Background Isolated 20q deletion [del(20q)] is a recurrent favorable abnormality in myelodysplastic syndrome (MDS) and may cause deletion of the ASXL1 gene. Meanwhile, ASXL1 mutations are also common in individuals with MDS. This study aim…

The Molecular Features of Chronic Eosinophilic Leukemia, Not Otherwise Specified Open

Shiqiang Qu, Ningning Liu, Qi Sun, Huijun Wang, Yujiao Jia , et al. · 2025

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes Open

Zhijian Xiao, Fuhui Li, Yudi Zhang, Chengwen Li, Qi Sun , et al. · 2024

GATA1 is one of critical transcription factors for megakaryopoiesis and platelet production. Our study aimed to explore the correlations between GATA1 expression and dysmegakaryopoiesis in myelodysplastic syndromes (MDS). Data of blood cel…

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis Open

Fuhui Li, Tiejun Qin, Bing Li, Shiqiang Qu, Lijuan Pan , et al. · 2024

We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN- SF3B1 -T) who were diagnosed according to the 2022 World Health Organization (WHO) classi…

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations Open

Xin Wang, Zhijian Xiao, Tiejun Qin, Zefeng Xu, Yujiao Jia , et al. · 2024

Myelodysplastic syndromes (MDS) patients with DEAD-box helicase 41 (DDX41) mutations have been reported to be treated effectively with lenalidomide; however, there are no randomized studies to prove it. Venetoclax and azacitidine ar…

Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms Open

Peiwen Zhang, Na You, Yiyi Ding, Wenqi Zhu, Nan Wang , et al. · 2024

Predicting survival in myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis Open

Zhijian Xiao, Fuhui Li, Tiejun Qin, Bing Li, Shiqiang Qu , et al. · 2024

We interrogated data from 180 consecutive subjects with myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) diagnosed according to the 2022 World Health Organization (WHO) classification of …

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins Open

Huijun Huang, Jinqin Liu, Lin Yang, Yiru Yan, Meng Chen , et al. · 2023

Ruxolitinib is a cornerstone of management for some subsets of myeloproliferative neoplasms (MPNs); however, a considerable number of patients respond suboptimally. Here, we evaluated the efficacy of micheliolide (MCL), a natural guaianoli…

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement Open

Yiru Yan, Shiqiang Qu, Jinqin Liu, Chengwen Li, Xiao‐Jie Yan , et al. · 2023

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms. Open

Zhongxun Shi, Jinqin Liu, Yingying Zhao, Lin Yang, Ya’nan Cai , et al. · 2023

Apart from the central role of the activated JAK/STAT signaling pathway, ASXL1 mutations are the most recurrent additional mutations in myeloproliferative neoplasms and occur much more commonly in myelofibrosis than in essential thrombocyt…

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression Open

Xin Yan, Zefeng Xu, Peihong Zhang, Qi Sun, Yujiao Jia , et al. · 2023

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy Open

Shiqiang Qu, Yiru Yan, Chengwen Li, Zefeng Xu, Wenyu Cai , et al. · 2023

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes Open

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu , et al. · 2022

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms Open

Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu , et al. · 2022

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes Open

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu , et al. · 2022

There are considerable new data on mutation topography in persons with myelodysplastic syndromes (MDS). These data have been used to update conventional risk models such as the Revised International Prognostic Scoring System (IPSS-R). Whet…

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms Open

Zhongxun Shi, Jinqin Liu, Yingying Zhao, Lin Yang, Ya’nan Cai , et al. · 2022

Apart from the central role of the activated JAK/STAT signaling pathway, ASXL1 mutations are the most recurrent additional mutations in myeloproliferative neoplasms and occur much more commonly in myelofibrosis than in essential thrombocyt…

Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells Open

Bingqing Luo, Fang Dong, Tiejun Qin, Qingyun Zhang, Haitao Bai , et al. · 2022

Myelodysplastic syndromes (MDS) are generally considered as a group of clonal diseases derived from hematopoietic stem cells, but a number of studies have suggested that they are derived from myeloid progenitor cells. We aimed to identify …

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center Open

Dan Liu, Zefeng Xu, Peihong Zhang, Tiejun Qin, Xiujuan Sun , et al. · 2022

Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center Data are presented as median (interquartile range…

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant Open

Shiqiang Qu, Donglei Zhang, Zefeng Xu, Yujiao Jia, Tiejun Qin , et al. · 2022

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera Open

Dan Liu, Zefeng Xu, Peihong Zhang, Tiejun Qin, Bing Li , et al. · 2021

RBC distribution width predicts thrombosis risk in polycythemia vera Open

Dan Liu, Bing Li, Zefeng Xu, Peihong Zhang, Tiejun Qin , et al. · 2021

Author response for "Is race important in genomic classification of hematological neoplasms?" Open

Huijun Huang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu , et al. · 2021

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes Open

Xiaofei Ai, Bing Li, Zefeng Xu, Jinqin Liu, Tiejun Qin , et al. · 2021

This study aimed to compare interphase fluorescence in situ hybridization (iFISH) and multiplex ligation dependent probe amplification (MLPA) for identifying genetic changes in myelodysplastic syndromes (MDS). The frequencies of cytogeneti…

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder Open

Huijun Huang, Wenjun Zhang, Wenyu Cai, Jinqin Liu, Huijun Wang , et al. · 2021

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study Open

Naibo Hu, Tiejun Qin, Xiaoyan Du, Feng Wang, Xiaoyun Wang , et al. · 2021

BACKGROUND Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and sa…

Tiejun Qin YOU? Author Swipe